Hi -,
Most people in the peptide world have never heard of PCAC. That's about to change.
It's the FDA advisory committee that helps decide which bulk substances pharmacies can legally compound. On July 23 and 24, 2026, it's taking up a list that reads like a peptide greatest hits: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon.
These are the compounds that have lived for years in the gray zone between heavy internet demand and anything resembling a clean legal pathway. This meeting is where some of that finally gets answered, at least for one round.
The last time PCAC looked at peptides, in December 2024, it wasn't close. AOD-9604 went down 0-12. CJC-1295 lost unanimously. Thymosin alpha-1 got buried 4-17. Being popular didn't save any of them.
So July isn't a victory lap waiting to happen. It's a real test, and FDA has already flagged most of these same peptides for safety concerns it hasn't put to rest. The question on the table isn't whether these peptides are interesting. It's whether they can be made, dosed, and checked safely enough to belong in a pharmacy at all.
There's also a clock most people will miss. Public comments close July 22, and anything submitted by July 9 actually reaches the committee before they vote. If you have a reason to weigh in, that window is the whole opportunity.
I wrote up the full breakdown: what PCAC can and can't do, who's actually in the room (and the empty seats nobody's talking about), the four boxes every one of these peptides has to check, and what the December votes tell us about which arguments are starting to work.
If you are interested in these compounds, this is the one to read before July.
